Poisoned in the Womb: When Medicine's Mistakes Echo Through Generations - Jill Escher (#19)
26 June 2025
With Jill Escher
Global
Jill Escher, autism advocate and president of the National Council on Severe Autism, discovered that her mother received weekly synthetic steroid hormone injections during pregnancy. In this episode she draws connections between prenatal pharmaceutical exposure — including DES and modern anti-miscarriage drugs — and rising rates of both autism and gender dysphoria. For Ireland, where referrals to gender services have grown sharply and questions about the drivers of that rise remain largely unanswered, Escher's research raises questions that clinicians and policymakers cannot afford to ignore.
Jill Escher is not a scientist by training, but she became one out of necessity. After raising two profoundly autistic sons and finding no adequate explanations in the standard genetic literature, she turned to her family's medical records and made a discovery that altered everything: her mother had received regular injections of synthetic steroid hormones throughout her pregnancy in 1965. That single finding sent Escher on a years-long investigation into prenatal pharmaceutical exposure and its potential to reshape neurodevelopment not just in the children directly exposed, but in the grandchildren too. The drug at the centre of the historical discussion is DES, or diethylstilbestrol, a synthetic oestrogen once prescribed to prevent miscarriage and pregnancy complications. DES was used across many countries from the late 1940s through the early 1970s. Its most visible harms — clear-cell vaginal cancer in daughters, reproductive abnormalities in sons — were recognised only decades after the drug was withdrawn. Escher's argument is that the neurological effects have received far less attention and may extend to subsequent generations through epigenetic mechanisms: alterations in gene expression that do not change the underlying DNA sequence but can nonetheless be inherited. The episode explores how synthetic hormones administered during critical windows of foetal brain development could plausibly alter the neural architecture underlying a range of conditions, including those on the autism spectrum. Escher does not confine her concern to DES alone. She points to other synthetic progestogens and hormones prescribed to pregnant women — some still in clinical use until 2023 — and argues that the medical establishment has been slow, and in some cases actively reluctant, to examine the cumulative and multigenerational effects of these drugs on the developing brain. The connection Escher draws to gender dysphoria is perhaps the most striking element of the conversation. Research has consistently found elevated rates of autism and other neurodevelopmental conditions among young people presenting at gender clinics, a pattern documented in studies across several countries. If a portion of that neurodivergence is itself a downstream consequence of pharmaceutical exposures in earlier generations, then the question of what is driving the extraordinary recent increase in gender dysphoria presentations becomes considerably more complex. It is a question with direct relevance in Ireland, where referrals to the national gender service have grown sharply and where the clinical and policy response remains a matter of active public debate. Escher is candid about the speculative elements in her framework and explicit in calling for formal research rather than claiming proof. What she is asking for — rigorous, adequately funded investigation into the multigenerational neurological effects of prenatal pharmaceutical exposures — is a reasonable demand. The episode makes the case that medical institutions have a poor track record of acknowledging iatrogenic harm, and that silence around this particular hypothesis is itself worth examining. Before assuming that rising rates of gender dysphoria are explained primarily by greater social acceptance and improved identification, it is worth holding open the question of what environmental and pharmaceutical factors may also be at work.
